发明名称 |
Glycolipid containing compositions for use in the treatment of tumours |
摘要 |
The invention relates to pharmaceutical compositions comprising α-Gal BOEL for use in treating patients with tumours. The invention also relates to methods of treating tumours using said compositions. The invention discloses that following intratumoural injection of α- Gal BOEL, binding of the natural anti-Gal antibody to de novo expressed tumoural α-Gal epitopes induces inflammation resulting in an anti-Gal antibody mediated opsonization of tumour cells and their uptake by antigen presenting cells. These antigen presenting cells migrate to draining lymph nodes and activate tumour specific T cells thereby converting the treated tumour lesions into in situ autologous tumour vaccines. This therapy can be applied to patients with multiple lesions and in neo-adjuvant therapy to patients before tumour resection. In addition to the regression and/or destruction of the treated tumour, such a vaccine will help in the immune mediated destruction of micrometastases that are not detectable during the removal of the treated tumour. The invention further teaches the enhancement of anti-tumour α-Gal BOEL treatment by the use of antibodies that inhibit the activity of immunological checkpoints molecules. |
申请公布号 |
AU2015257496(A1) |
申请公布日期 |
2016.11.10 |
申请号 |
AU20150257496 |
申请日期 |
2015.05.08 |
申请人 |
Agalimmune Limited |
发明人 |
Galili, Uri;Pickford, Christopher;Griffiths, Graham John Charles |
分类号 |
A61K31/7032;A61P35/00 |
主分类号 |
A61K31/7032 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|